Erratum

Erratum to “Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study” [Schizophrenia Research 113 (2009) 112–121]†

Emilio Sacchetti a,b,c,d,*, Alessandro Galluzzo b,c, Paolo Valsecchi b,c, Fabio Romeo e, Barbara Gorini e, Lewis Warrington f and on behalf of the MOZART Study Group

a Chair of Psychiatry, Brescia University School of Medicine, Brescia, Italy
b University Psychiatric Unit, Brescia University School of Medicine and Brescia Spedali Civili, Brescia, Italy
c Department of Mental Health, Brescia Spedali Civili, Brescia, Italy
d Center of Behavioral and Neurodegenerative Disorders, Brescia University and EULO, Brescia, Italy
e Medical Department, Pfizer Italia, Rome, Italy
f Pfizer Inc, New York, NY, USA

The publisher regrets that an error occurred in the list of investigators that appear in the Acknowledgement section of this article. The corrected version appears below. The publisher would like to apologise for any inconvenience caused.

Acknowledgments


This study was funded by Pfizer, Italy and carried out with the support of Pfizer, Inc.

Prof. Sacchetti, Drs. Galluzzo and Valsecchi, and the Investigator of the MOZART Study Group have all worked as consultants for Pfizer, Italy. Drs. Romeo, Gorini and Warrington are or were full time employees of Pfizer, Italy or Pfizer Inc at the time of the study and development of this manuscript.

DOI of original article: 10.1016/j.schres.2009.02.017.

* Corresponding author. University Psychiatric Unit, Spedali Civili, p.le Spedali Civili 1, 25133 Brescia, Italy. Tel.: +39 30 3995233, +39 30 381749; fax: +39 30 3394089.
E-mail address: sacchetti@med.unibs.it (E. Sacchetti).

0920-9964/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.schres.2010.05.002